A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Summary

This is a one-arm phase II clinical study. In patients with stage III-IVA cervical cancer with pelvic lymph nodes \> 2cm, positive para-aortic lymph nodes, or lymph node metastases \> 2, patients with positive PD-L1 expression (CPS score ≥1) were treated with cararizumab combined with conventional concurrent chemoradiotherapy and immunomaintenance therapy for one year. To evaluate the efficacy and safety of carilizumab in combination with concurrent chemoradiotherapy and subsequent maintenance therapy.

Timeline

Start

2021-12-01

Primary completion

2023-12-12

Completion

2023-12-12

Drugs

Indications